1. Evaluation the safety of using human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis. 2. Observe the curative effect of patients with hepatitis B cirrhosis who use human umbilical mesenchymal stem cells to treat. 3. Explore the possible mechanism of human umbilical mesenchymal stem cells to treat patients with hepatitis B cirrhosis.
Age 18-60 years old, gender not limited, body mass index (BMI) between 19-25 kg/m2, including boundary value;
The diagnosis of hepatitis B cirrhosis was in line with the 2015 American society of hepatology (AASLD) guidelines for the treatment of chronic hepatitis B, and the liver function grade was child-pugh B or child-pugh C, with a score range of 7-12 points, and Model for End-Stage Liver Disease score≤21 points.
Have not received stem cell therapy in the recent 6 months;
Subjects will be able to sign the informed consent in accordance with the study procedures and instructions.
Insufficiency of vital organs, such as heart, kidney and lung;
End-stage cirrhosis with severe complications, including but not limited to: hepatic encephalopathy, gastrointestinal bleeding,Severe bleeding tendency, massive ascites, etc.
Concomitant peritonitis, pneumonia, or other types of infection not under control;
Have a history of severe allergic reaction or allergy to two or more kinds of food or medicine;